Christopher Ryan Sullivan, Chief Financial Officer at Avalo Therapeutics, Inc. (AVTX), sold 18,606 shares at $24.12 ($449K) on 2026-05-07, disclosed to the SEC on 2026-05-11.
Scheduled sale ($449k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| AVTX | SELL | 2026-08-19 | $1.5M | — | Filing → |
| AVTX | SELL | 2026-05-07 | $949K | — | Filing → |
| AVTX | SELL | 2026-05-01 | $223K | — | Filing → |